The next-generation ultrasound system reportedly offers enhanced images through graphic-based beamforming technology, a variety of artificial intelligence (AI)-powered tools and reduced exam times.
Expanding upon its women’s health portfolio, GE Healthcare has launched the Voluson Expert 22 ultrasound system.
Providing enhanced imaging capabilities through the device’s Lyric Architecture, the Voluson Expert 22 ultrasound system accommodates a variety of body sizes, according to the company. Combining new levels of penetration and frame rates, GE Healthcare said the new system provides enhanced anatomical detail on a 23.8 inch high-definition ultrasound display with increased contrast and spatial resolution.
“The Voluson Expert 22 is a masterpiece of engineering with exceptional 2D images from thin to difficult scanning patients. This machine also has the outstanding ergonomics and is the most customizable system ever produced, It is one of the best ultrasound machines I have ever used,” noted Rabih Chaoui, M.D., the managing director at the Center for Prenatal Diagnosis and Human Genetics in Berlin, Germany.
In addition to a user interface that allows personalized preferences and automated probe presets, the Voluson Expert 22 offers a variety of artificial intelligence (AI)-enabled tools. GE Healthcare noted that SonoLyst provides annotations and measurements that improve the efficiency of viewing fetal anatomy by up to 65 percent. Facilitating consistent measurements and enhanced alignment of 3D views of the fetal brain, the SonoCNS feature reportedly reduces exam time by 81 percent, according to the company.
“By using AI, we are pushing limits and enhancing diagnostic capabilities. At the same time, the functionality makes exams easier. The AI built into this machine is so far advanced compared to what we’ve seen before, and it’s only a hint. It’s our responsibility to push it even further by using it, challenging it, and showing it makes a difference,” said Lawrence Platt, M.D., an obstetrician-gynecologist at the Center for Fetal Medicine in Los Angeles.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
2 Commerce Drive
Cranbury, NJ 08512